Company news
Poolbeg Pharma Plc (LSE:POLB) news
Poolbeg Pharma Plc news releases on 6ix. Latest, Aug 27, 2024: H.C. Wainwright Global Investment Conference
Press releases — page 2
H.C. Wainwright Global Investment Conference
August 27, 2024
Poolbeg Pharma plc - Voluntary Delisting from OTCQB Market
July 29, 2024
Voluntary Delisting from OTCQB Market
July 26, 2024
Change of Registered Address
July 2, 2024
Result of AGM
June 17, 2024
Poolbeg Pharma plc - Annual Report and AGM Notice
May 10, 2024
Annual Report & AGM Notice
May 9, 2024
Poolbeg Pharma's POLB 001 immuno-modulator II receives fully-granted patent from US Patent Office
May 8, 2024
Significant POLB 001 Patent Granted in USA
May 1, 2024
Appointment of Joint Broker
April 30, 2024
Option Agreement to Acquire Orphan Drug Candidate
April 30, 2024
Results for the year ended 31 December 2023
April 30, 2024
TR-1: Notification of major holdings
April 29, 2024
POLB 001 US Patent Update
March 20, 2024
Poolbeg Pharma plc - Director Share Purchase
February 23, 2024
Director Share Purchase
February 19, 2024
Board Role Change and Launch of EIP
February 15, 2024
Market Opportunity for POLB 001 for CRS
February 12, 2024
Poolbeg Pharma plc - Further Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome
January 18, 2024
Further data shows POLB001 potential in cancer CRS
January 17, 2024
RSV AI Drug Candidate Analysis Update
December 20, 2023
Poolbeg Pharma plc - POLB 001 Data Presented at ASH
December 12, 2023
POLB 001 Data Presented at ASH
December 11, 2023
Directorate Change
November 30, 2023
Poolbeg Pharma plc - Immunomodulator II patent granted in Japan
November 22, 2023
Immunomodulator II patent granted in Japan
November 21, 2023
Poolbeg Pharma plc - POLB 001 LPS Challenge Trial Data to be presented at IUIS
November 17, 2023
POLB 001 LPS Trial Data to be Presented at IUIS
November 16, 2023
Former Amryt Pharma Leadership Team join Poolbeg
November 9, 2023
POLB001 Data to be Presented at ASH Annual Meeting
November 3, 2023
POLB 001 Oncology Programme Update Meeting
November 1, 2023
SAB Endorses Influenza Drug Targets
October 26, 2023
Poolbeg Partners with a Nasdaq-Listed Biopharma
October 17, 2023
Favourable Conclusion of Patent Opposition
September 29, 2023
Immunomodulator I Patent Portfolio Strengthened
September 20, 2023
Immunomodulator I Patent Opposition Withdrawal
September 19, 2023
Interim results for the six months to 30 June 2023
September 13, 2023
AI led programme identifies influenza drug targets
June 29, 2023
Oral Vaccine Programme Moves Forward
June 22, 2023
Board Appointment
May 24, 2023
Results of Annual General Meeting
May 11, 2023
Results for the year ended 31 December 2022
March 30, 2023
POLB 001 patent portfolio strengthened
March 8, 2023
Second Price Monitoring Extn
March 2, 2023
Price Monitoring Extension
March 2, 2023
Positive Results POLB001 LPS Human Challenge Trial
March 2, 2023
Strategic expansion of POLB 001 into oncology
January 16, 2023
Positive Initial Data Analysis in POLB 001 Trial
January 9, 2023
Poolbeg Pharma identifies new RSV drug candidates
December 22, 2022
Poolbeg identifies novel RSV drug candidates
December 21, 2022